TB-500

Thymosin beta-4 fragment (17-23) · Hudson Biotech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TB-500, covering 2026-03-23 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD [Phase 1, Phase 2]